Screening for ovarian cancer in the general population

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 26, Issue 2, 2012, Pages 243-256

  Gentry Maharaj, Aleksandra ^a   Menon, Usha ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CA125; general population; ovarian cancer; screening; tumour markers; ultrasound

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; RISK; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 84858747280     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.11.006     Document Type: Article

References (101)

1. Cancer Research UK. CancerStats: Ovarian cancer UK incidence statistics; http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence/ [last accessed 05.11.11].
2. Cancer Research UK. CancerStats: ovarian cancer molecular biology and genetics; http://info.cancerresearchuk.org/cancerstats/types/ovary/ molecularbiologyandgenetics/ [last accessed 05.11.11].
3. J.D. Seidman, I. Horkayne-Szakaly, and M. Haiba The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin Int J Gynecol Pathol 23 2004 41 44 (Pubitemid 38018236)
4. Cancer Research UK. CancerStats: ovarian cancer survival statistics; http://info.cancerresearchuk.org/cancerstats/types/ovary/survival/#stage [last accessed 05.11.11].
5. IARC Cancer screening in the European Union, in IARC cancer prevention: cancer screening manuals and guidelines 2003 International Agency for Research on Cancer Lyon pp. 85-88
6. U. Menon, and I. Jacobs Screening for ovarian cancer Best Pract Res Clin Obstet Gynaecol 16 2002 469 482 (Pubitemid 41123402)
7. R.J. Kurman, and IeM. Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 2010 433 443
8. C.P. Crum, R. Drapkin, and A. Miron The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 2007 3 9 (Pubitemid 46095865)
9. M.J. Duffy, J.M. Bonfrer, and J. Kulpa CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Int J Gynecol Cancer 15 2005 679 691 (Pubitemid 41783071)
10. I. Jacobs, and U. Menon The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples Cancer Prev Res 4 3 2011 299 302
11. M.S. Pepe, Z. Feng, and H. Janes Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 2008 1432 1438
12. R.C. Bast Jr., M. Feeney, and H. Lazarus Reactivity of a monoclonal antibody with human ovarian carcinoma J Clin Invest 68 1981 1331 1337 (Pubitemid 12235035)
13. B.W. Yin, and K.O. Lloyd Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16 J Biol Chem 276 2001 27371 27375
14. E.M. Davelaar, G.J. van Kamp, and R.A. Verstraeten Comparison of seven immunoassays for the quantification of CA 125 antigen in serum Clin Chem 44 1998 1417 1422 (Pubitemid 28309100)
15. S.E. Kabawat, R.C. Bast Jr., and A.K. Bhan Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125 Int J Gynecol Pathol 2 1983 275 285 (Pubitemid 14176989)
16. E.J. Nouwen, P.G. Hendrix, and S. Dauwe Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study Am J Pathol 126 1987 230 242 (Pubitemid 17033849)
17. I. Jacobs, and R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Hum Reprod 4 1989 1 12 (Pubitemid 19069900)
18. M.K. Tuxen, G. Soletormos, and P. Ombernowsky Tumor markers in the management of patients with ovarian cancer Cancer Treat Rev 21 1995 215 245
19. R.C. Bast Jr., T.L. Klug, and E. St John A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887 (Pubitemid 13014028)
20. G.G. Bon, P. Kenemans, and P. Verstraeten Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values Am J Obstet Gynecol 174 1996 107 114 (Pubitemid 26037697)
21. V.R. Zurawski Jr., H. Orjaseter, and A. Andersen Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer Int J Cancer 42 1988 677 680 (Pubitemid 19008906)
22. T. Alagoz, R.E. Buller, and M. Berman What is a normal CA125 level? Gynecol Oncol 53 1994 93 97 (Pubitemid 24136908)
23. J.M. Bonfrer, C.M. Korse, and R.A. Verstraeten Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value Clin Chem 43 1997 491 497 (Pubitemid 27106485)
24. A.R. Jeyarajah, T.E. Ind, and S. Skates Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women Cancer 85 1999 2068 2072 (Pubitemid 29202783)
25. K. Sjovall, B. Nilsson, and N. Einhorn The significance of serum CA 125 elevation in malignant and nonmalignant diseases Gynecol Oncol 85 2002 175 178 (Pubitemid 34304030)
26. A. Gentry-Maharaj, S. Skates, and A. Sharma Risk of Ovarian Cancer (ROC) Algorithm Increases Specificity of Ca125 in Ovarian Cancer Screening Int J Gynecol Canc 16 October 2006 600 601
27. H. Kobayashi, H. Ooi, and Y. Yamada Serum CA125 level before the development of ovarian cancer Int J Gynaecol Obstet 99 2007 95 99 (Pubitemid 47561911)
28. D.W. Cramer, D.J. O'Rourke, and A.F. Vitonis CA125 immune complexes in ovarian cancer patients with low CA125 concentrations Clin Chem 56 2010 1889 1892
29. N. Einhorn, K. Sjovall, and R.C. Knapp Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer Obstet Gynecol 80 1992 14 18
30. I. Jacobs, A.P. Davies, and J. Bridges Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography BMJ 306 1993 1030 1034 (Pubitemid 23105960)
31. I.J. Jacobs, S. Skates, and A.P. Davies Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study BMJ 313 1996 1355 1358 (Pubitemid 26400120)
32. U. Menon, A. Talaat, and A.R. Jeyarajah Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation Br J Cancer 80 1999 1644 1647 (Pubitemid 29308649)
33. U. Menon, A. Talaat, and A.N. Rosenthal Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening BJOG 107 2000 165 169 (Pubitemid 30081580)
34. I.J. Jacobs, S.J. Skates, and N. MacDonald Screening for ovarian cancer: a pilot randomised controlled trial Lancet 353 1999 1207 1210 (Pubitemid 29168457)
35. S.J. Skates, U. Menon, and N. MacDonald Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women J Clin Oncol 21 10 Suppl. 2003 206 210
36. S.J. Skates, F.J. Xu, and Y.H. Yu Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers Cancer 76 10 Suppl. 1995 2004 2010
37. S.J. Skates, D.K. Pauler, and I.J. Jacobs Screening based on risk of cancer calculation from Bayesian hierarchical change point and mixture models of longitudinal markers J Am Stat Assoc 96 454 2001 429 435
38. U. Menon, A. Gentry-Maharaj, and R. Hallett Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Lancet Oncol 10 2009 327 340
39. U. Menon, S.J. Skates, and S. Lewis Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer J Clin Oncol 23 2005 7919 7926 (Pubitemid 46657391)
40. U. Menon, A. Gentry-Maharaj, and A. Ryan Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study BMJ 337 2008 a2079
41. K.H. Lu, S. Skates, and T.B. Bevers A prospective US ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) J Clin Oncol 28 2010 [suppl; abstract 5003]
42. A. Rosenthal, and I. Jacobs Familial ovarian cancer screening Best Pract Res Clin Obstet Gynaecol 20 2006 321 338 (Pubitemid 43380603)
43. M.W. McIntosh, and N. Urban A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker Biostatistics 4 2003 27 40 (Pubitemid 36116886)
44. M.J. Engelen, H.E. Kos, and P.H. Willemse Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma Cancer 106 2006 589 598 (Pubitemid 43157622)
45. K.C. Giede, K. Kieser, and J. Dodge Who should operate on patients with ovarian cancer? An evidence-based review Gynecol Oncol 99 2005 447 461 (Pubitemid 41502860)
46. T. Paulsen, K. Kjaerheim, and J. Kaern Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals Int J Gynecol Cancer 16 Suppl. 1 2006 11 17
47. P.O. van Trappen, B.D. Rufford, and T.D. Mills Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy Int J Gynecol Cancer 17 2007 61 67 (Pubitemid 46213971)
48. I. Hellstrom, J. Raycraft, and M. Hayden-Ledbetter The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 2003 3695 3700 (Pubitemid 36793054)
49. R.G. Moore, A.K. Brown, and M.C. Miller The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2008 402 408 (Pubitemid 351174295)
50. F. Jacob, M. Meier, and R. Caduff No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting Gynecol Oncol 121 3 2011 487 491
51. R.G. Moore, D.S. McMeekin, and A.K. Brown A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 2009 40 46
52. D.W. Cramer, R.C. Bast Jr., and C.D. Berg Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prev Res 4 3 2011 365 374
53. Z. Zhang, Y. Yu, and F. Xu Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer Gynecol Oncol 107 2007 526 531 (Pubitemid 350160868)
54. D. Lu, E. Kuhn, and R.E. Bristow Comparison of candidate serologic markers for type I and type II ovarian cancer Gynecol Oncol 122 2011 560 566
55. I. Visintin, Z. Feng, and G. Longton Diagnostic markers for early detection of ovarian cancer Clin Cancer Res 14 2008 1065 1072 (Pubitemid 351302552)
56. G.L. Anderson, M. McIntosh, and L. Wu Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J Natl Cancer Inst 102 1 2010 26 38
57. C.S. Zhu, P.F. Pinsky, and D.W. Cramer A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer Cancer Prev Res 4 3 2011 375 383
58. C.L. Bailey, F.R. Ueland, and G.L. Land The malignant potential of small cystic ovarian tumors in women over 50 years of age Gynecol Oncol 69 1998 3 7 (Pubitemid 28201664)
59. L. Valentin, L. Skoog, and E. Epstein Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation Ultrasound Obstet Gynecol 22 2003 284 289 (Pubitemid 37088554)
60. E. Ferrazzi, G. Zanetta, and D. Dordoni Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study Ultrasound Obstet Gynecol 10 1997 192 197 (Pubitemid 27472453)
61. J.P. Lerner, I.E. Timor-Tritsch, and A. Federman Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system Am J Obstet Gynecol 170 1 Pt 1 1994 81 85 (Pubitemid 24084035)
62. B.W. Mol, D. Boll, and M. De Kanter Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models Gynecol Oncol 80 2001 162 167 (Pubitemid 32158453)
63. A.M. Sassone, I.E. Timor-Tritsch, and A. Artner Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy Obstet Gynecol 78 1991 70 76
64. D. Timmerman, T.H. Bourne, and A. Tailor A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model Am J Obstet Gynecol 181 1999 57 65 (Pubitemid 29343331)
65. F.R. Ueland, P.D. DePriest, and E.J. Pavlik Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography Gynecol Oncol 91 2003 46 50 (Pubitemid 37188592)
66. S. Granberg, M. Wikland, and I. Jansson Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation Gynecol Oncol 35 1989 139 144 (Pubitemid 19268545)
67. S.C. Modesitt, E.J. Pavlik, and F.R. Ueland Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter Obstet Gynecol 102 2003 594 599 (Pubitemid 37311227)
68. A. Sharma, A. Gentry-Maharaj, and M. Burnell Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study BJOG 2011
69. L. Valentin, and D. Akrawi The natural history of adnexal cysts incidentally detected at transvaginal ultrasound examination in postmenopausal women Ultrasound Obstet Gynecol 20 2002 174 180 (Pubitemid 35300715)
70. M. Hirai, Y. Hirai, and T. Tsuchida Stage IA ovarian cancers: comparison of sonographic findings and histopathologic types between patients with normal and elevated serum cancer antigen 125 levels J Ultrasound Med 30 7 2011 943 952
71. I. Jacobs, D. Oram, and J. Fairbanks A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 1990 922 999
72. P. Geomini, R. Kruitwagen, and G.L. Bremer The accuracy of risk scores in predicting ovarian malignancy: a systematic review Obstet Gynecol 113 2 Pt 1 2009 384 394
73. L.S. Cohen, P.F. Escobar, and C. Scharm Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction Gynecol Oncol 82 2001 40 48 (Pubitemid 32634952)
74. A. Kurjak, S. Kupesic, and V. Sparac Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions Ultrasound Obstet Gynecol 16 2000 365 371 (Pubitemid 32154675)
75. P.M. Geomini, S.F. Coppus, and K.B. Kluivers Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses? Gynecol Oncol 106 2007 153 159 (Pubitemid 46898583)
76. R.D. Clayton, S. Snowden, and M.J. Weston Neural networks in the diagnosis of malignant ovarian tumours Br J Obstet Gynaecol 106 1999 1078 1082 (Pubitemid 29457092)
77. A. Tailor, D. Jurkovic, and T.H. Bourne Sonographic prediction of malignancy in adnexal masses using an artificial neural network Br J Obstet Gynaecol 106 1999 21 30 (Pubitemid 29041971)
78. D. Timmerman, H. Verrelst, and T.H. Bourne Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses Ultrasound Obstet Gynecol 13 1999 17 25 (Pubitemid 29097173)
79. L. Valentin, B. Hagen, and S. Tingulstad Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation Ultrasound Obstet Gynecol 18 2001 357 365 (Pubitemid 32947204)
80. D. Timmerman Lack of standardization in gynecological ultrasonography Ultrasound Obstet Gynecol 16 2000 395 398 (Pubitemid 32158113)
81. B. Van Calster, D. Timmerman, and T. Bourne Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125 J Natl Cancer Inst 99 2007 1706 1714 (Pubitemid 351767215)
82. L. Valentin Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound Ultrasound Obstet Gynecol 14 1999 338 347 (Pubitemid 30032358)
83. J.R. van Nagell Jr., P.D. Depriest, and F.R. Ueland Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened Cancer 109 2007 1887 1896 (Pubitemid 46668555)
84. H. Kobayashi, Y. Yamada, and T. Sado A randomized study of screening for ovarian cancer: a multicenter study in Japan Int J Gynecol Cancer 18 2008 414 420 (Pubitemid 351668303)
85. S.S. Buys, E. Partridge, and M.H. Greene Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial Am J Obstet Gynecol 193 2005 1630 1639 (Pubitemid 41540458)
86. E. Partridge, A.R. Kreimer, and R.T. Greenlee Results from four rounds of ovarian cancer screening in a randomized trial Obstet Gynecol 113 2009 775 782
87. S.S. Buys, E. Partridge, and A. Black Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 2011 2295 2303
88. U. Menon, A. Gentry-Maharaj, and I. Jacobs Ovarian cancer screening and mortality JAMA 306 14 2011 Oct 12 1544
89. H. Song, S.J. Ramus, and J. Tyrer A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 Nat Genet 41 2009 996 1000
90. E.L. Goode, G. Chenevix-Trench, and H. Song A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 Nat Genet 42 2010 874 879
91. S. Chen, and G. Parmigiani Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 2007 1329 1333 (Pubitemid 46706879)
92. M. Aarnio, R. Sankila, and E. Pukkala Cancer risk in mutation carriers of DNA-mismatch-repair genes Int J Cancer 81 1999 21 48
93. I. Jacobs Screening for familial ovarian cancer: the need for well-designed prospective studies J Clin Oncol 23 2005 5443 5445
94. R. Manchanda, A. Rosenthal, and M. Burnell Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers J Med Genet 46 2009 423 424
95. A.N. Rosenthal, L. Fraser, and R. Manchanda The UK Familial Ovarian Cancer Screening Study (UK FOCSS): phase 1: results Of annual screening 2009 British Gynaecological Cancer Society Dublin, Ireland
96. M.H. Greene, M. iedmonte, and D. Alberts A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study Cancer Epidemiol Biomarkers Prev 17 2008 594 604 (Pubitemid 351469209)
97. C.R. Bankhead, S.T. Kehoe, and J. Austoker Symptoms associated with diagnosis of ovarian cancer: a systematic review BJOG 112 2005 857 865 (Pubitemid 40896949)
98. B.A. Goff, L.S. Mandel, and C.W. Drescher Development of an ovarian cancer symptom index: possibilities for earlier detection Cancer 109 2007 221 227 (Pubitemid 46106236)
99. M.R. Andersen, B.A. Goff, and K.A. Lowe Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer Gynecol Oncol 116 2010 378 383
100. B.D. Rufford, I.J. Jacobs, and U. Menon Feasibility of screening for ovarian cancer using symptoms as selection criteria BJOG 114 2007 59 64 (Pubitemid 44923933)
101. V. Nosov, F. Su, and M. Amneus Validation of serum biomarkers for detection of early-stage ovarian cancer Am J Obstet Gynecol 200 6 2009 639 e1-e5